# In vivo virulence of *Staphylococcus aureus* in native versus prosthetic left-sided valve endocarditis



Haytham Elgharably, MD, <sup>a</sup> Jan Claesen, PhD, <sup>b,c</sup> Naseer Sangwan, PhD, <sup>b,c,d</sup> Muhammad Etiwy, MD, <sup>a</sup> Penny Houghtaling, MS, <sup>a</sup> Gary W. Procop, MD, MS, <sup>e</sup> Nabin K. Shrestha, MD, <sup>f</sup> Brian Griffin, MD, <sup>g</sup> Jose L. Navia, MD, <sup>a</sup> Lars G. Svensson, MD, PhD, <sup>a</sup> Daniel J. Wozniak, PhD, <sup>h</sup> and Gosta B. Pettersson, MD, PhD<sup>a</sup>


# **ABSTRACT**

**Objectives:** Staphylococcus aureus infective endocarditis is commonly associated with invasive pathology and is worse in prosthetic valve endocarditis. In this study, we aim to examine *S. aureus* virulence and pathological features of native and prosthetic valve infective endocarditis.

**Methods:** Between 2002 and 2020, 438 patients underwent surgery for left-sided endocarditis caused by *S. aureus* at our center (59% native and 41% prosthetic valve endocarditis). Endocarditis registry was queried, and pathological features were based on the echocardiography and operative findings. In addition, vegetation samples were collected from 6 patients undergoing surgery for infective endocarditis (3 native and 3 prosthetic valve endocarditis). Total RNA was extracted from all specimens, and messenger RNA sequencing was executed for transcriptomic analysis. Data were pooled into STAR aligner, and gene expression related to virulence factors was compared between 2 groups.

**Results:** Rates of invasive pathology were higher in prosthetic versus native valve infective endocarditis (76% vs 40%, P < .0001), which impacted the complexity of surgical procedures and perioperative course, but not in-hospital mortality. Transcriptomic analysis has shown differences in gene expression between vegetation specimens of native and prosthetic valve endocarditis, including genes for stress response, biofilm formation, and virulence factors. The gene *aur* (encodes for aureolysin) was highly upregulated in prosthetic valve vegetations compared with native valve vegetations (P = .023).

**Conclusions:** Prosthetic valve endocarditis caused by *S. aureus* is associated with further invasive pathology compared with native valve endocarditis, which could be related to upregulation of genes responsible for biofilm formation and metalloproteinase production. (JTCVS Open 2025;24:156-69)



Higher expression of *aur* (encodes for aureolysin) in PVE.

#### CENTRAL MESSAGE

PVE caused by *Staphylococcus* aureus is associated with further invasive pathology compared with NVE, which is secondary to the difference in virulence factors.

#### **PERSPECTIVE**

Transcriptomic profiling of *Staphylococcus aureus* colonizing cardiac vegetations has shown upregulation of aureolysin in prosthetic valve vegetation, which could explain the invasive pathology in the surrounding tissues. This finding warrants further investigations to develop novel diagnostics that can guide the clinical decision for the timing of surgery for endocarditis.

From the "Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Center for Microbiome and Human Health, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Microbial Sequencing & Analytics Resource (MSAAR) Facility, Lerner Research Institute, Cleveland, Ohio; Department Laboratory Medicine, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio; Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; and Departments of Microbial Infection and Immunity and Microbiology, Ohio State University, Columbus, Ohio.

This work is supported by The Research Program Committee (RPC#244) funding award from Lerner Research Institute at Cleveland Clinic to Drs Elgharably and Pettersson.

The study was approved by the Institutional Review Board (IRB#16-1521), and all participants were provided an information sheet before enrollment.

Received for publication Sept 22, 2024; revisions received Nov 23, 2024; accepted for publication Dec 3, 2024; available ahead of print Jan 9, 2025.

Address for reprints: Haytham Elgharably, MD, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Ave/Desk J4-1, Cleveland, OH 44195 (E-mail: Elgharh@ccf.org).

2666-2736

Copyright © 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.xjon.2024.12.004

### **Abbreviations and Acronyms**

IE = infective endocarditisNVE = native valve endocarditisPVE = prosthetic valve endocarditis

Despite the recent advances in medical therapies, infective endocarditis (IE) remains lethal with high mortality rates reaching 25%. 1,2 Advances in medicine have changed the epidemiology and microbiology of IE, but not the outcomes. Staphylococcus aureus has become the leading causative pathogen of IE.<sup>3,4</sup> S. aureus endocarditis is frequently associated with invasive pathology, especially with prosthetic valve endocarditis (PVE).<sup>5-7</sup> This could explain the increased perioperative mortality risk associated with S. aureus infection and PVE. 8-10 Previously, our group presented the hypothesis that IE is a biofilm-associated infection based on a constellation of clinical observations that are in accordance with the criteria of biofilm infection.<sup>1,3</sup> Growing evidence, including microscopic imaging, animal experiments, and in vitro studies, of IE bacterial isolates supports this hypothesis. 1,3,11 However, current studies do not provide a direct in vivo examination of microbial behavior within the cardiac vegetations in patients with IE. This is critical to better understand the mechanisms used by bacteria to evade the host immune response, resist antibiotics, and invade and destroy surrounding tissues. For instance, why is PVE more aggressive than native valve endocarditis (NVE) with respect to tissue invasion (Figure 1)?<sup>5,6</sup> Do bacterial cells modify their gene expression profile upon attachment to the cardiac valve tissue as aggregates of micro-colonies (Figure 2) followed by the production of virulence factors responsible for resistance and tissue invasion? Addressing these questions will have important clinical implications in guiding the current management strategies into more specific diagnostics and effective therapies for IE.

In this study, we hypothesize that PVE caused by *S. aureus* is associated with further invasive pathology than NVE, secondary to difference in virulence. To test this hypothesis, we examined the pathological features in a large cohort of patients who underwent surgery for *S. aureus* IE at our center. Additionally, we examined the difference in gene expression of *S. aureus* isolated from native and prosthetic valve vegetations harvested from 6 patients during surgery for endocarditis.

### **MATERIAL AND METHODS**

### **Infective Endocarditis Data Registry**

In our institution Endocarditis Registry database (a prospective registry established from institutional infectious disease and surgical registries for quality reporting); 2965 patients underwent surgery for IE from January 2002 to December 2020. Of these, 575 (19%) had established diagnosis of *S. aureus* endocarditis, of whom 523 had active endocarditis and 52

had remote endocarditis. Continuous variables are presented as mean  $\pm$  SD and as 15th, 50th (median), and 85th percentiles; comparisons were made using Wilcoxon rank-sum test. Categorical data are described using frequencies and percentages; comparisons were made using the chi-square test or Fisher exact test when frequency was less than 5. All analyses were performed using SAS statistical software (SAS v9.4; SAS, Inc). Invasive pathology is based on operative findings and defined as extension of infection from aortic valve leaflets into the annulus or beyond (eg, abscess or fistula).

### **Patients and Clinical Samples**

Specimens for transcriptomic profiling (RNA sequencing) were collected from a total of 6 patients (3 with NVE and 3 with PVE; Figure 3). Inclusion criteria involved established diagnosis of IE by an infectious disease specialist in addition to being classified as "definite" endocarditis by Duke Criteria, <sup>12</sup> positive *S. aureus* blood cultures, and referral for cardiac surgery. In this pilot study, samples were collected from the first 6 patients who fulfilled the inclusion criteria. The study protocol was approved by the Cleveland Clinic Institutional Review Board (#16-1521, January 16, 2017), and all participants were provided an information sheet before enrollment. During surgery for endocarditis, explanted valve vegetation specimens were collected and immediately preserved in 1 mL of TRIzol and stored at -80 °C (Invitrogen, Thermo Fisher Scientific, Inc). Samples were given serial codes when sent for RNA-sequencing and bioinformatics analysis to keep results blinded.

# **Blood Culture Bacterial Isolates**

For the 6 patients recruited in the study, corresponding bacterial isolates from positive preoperative blood cultures were obtained from the Cleveland Clinic microbiology laboratory. *S. aureus* blood culture isolate stocks were stored in tryptic soy broth with 15% glycerol (Hardy Diagnostics) at  $-70\,^{\circ}\mathrm{C}$  until subcultured for testing. Suspensions were prepared at a concentration of  $6\times10^{8}$  CFU/mL.

# Full Prokaryotic Messenger RNA Sequencing: TruSeq Stranded With RiboZero Plus (Human, Mouse, Rat, Bacteria)

RNA extraction was done using a Qiagen RNeasy Plus Mini Kit for all samples (blood culture isolates after growth in media and directly from frozen vegetation specimens). Isolated RNA sample quality was assessed by the BioAnalyzer Pico 6000 RNA Assay (Agilent Technologies Inc) and quantified by Qubit 2.0 RNA HS assay (ThermoFisher). Ribosomal RNA depletion was performed with a Ribo-Zero Plus rRNA Removal Kit (Illumina Inc). Subsequently, libraries were constructed by using a Truseq Stranded Total RNA kit (Illumina). Final library quantity was assessed by Qubit 2.0 (ThermoFisher), and quality was assessed by TapeStation D1000 ScreenTape (Agilent Technologies Inc). The average final library size was approximately 330 bp with an insert size of approximately 200 bp. Illumina 8-nt dual-indices were used. Equimolar pooling of libraries was performed based on QC values and sequenced (Novogene) on an Illumina NovaSeq S4 with a read length configuration of 150 paired-end for 40 M paired-end reads per sample (20 M in each direction).

### **Bioinformatics Analysis**

Quality control of the metagenomic reads was conducted as described previously. <sup>13</sup> Briefly, raw reads were processed for low-quality-based filtering using Trimmomatic pipeline. <sup>14</sup> Host-derived reads were excluded by mapping the reads to the reference human genome (GCF\_000001405.40) using BBMap software (sourceforge.net/projects/bbmap/). Reference microbial genomes were annotated using prokka. <sup>15</sup> Quality trimmed reads were processed for taxonomic and functional profiling STAR aligner against the bacterial reference genomes. <sup>16</sup> DAtest




FIGURE 1. Operative photograph showing large vegetation attached to prosthetic aortic valve in a patient with IE (A) and invasion and disintegration of the aortic root tissues after explant of the infected prosthetic valve (B).


package was used to benchmark the statistical tests. <sup>17</sup> Differential feature selection was performed using the Fisher exact t test. <sup>18</sup> We assessed the statistical significance (P < .05) throughout, and whenever necessary, we adjusted P values for multiple comparisons according to the Benjamini and Hochberg method to control the false discovery rate while performing multiple tests on taxa and pathway abundances according to sample types.

# **RESULTS**


### **Clinical Endocarditis Registry**

In our institution's Endocarditis Registry, we identified 438 patients who underwent surgery for left-sided

endocarditis caused by *S. aureus*, of whom 260 (59%) had NVE and 178 (41%) had PVE (Tables E1 and E2). For PVE, most cases had involvement of the aortic valve (81%), whereas for patients with NVE the mitral valve was more commonly affected (65%) (P < .0001). Invasive disease (76%) with cavity formation (44%) was significantly greater in PVE compared with NVE (40% and 10%, respectively) (P < .0001). Surgery for PVE more commonly required reconstruction of the aortic root with the aortic allograft (P < .0001), longer cardiopulmonary



**FIGURE 2.** Scanning electron microscope image of a porcine bioprosthetic aortic valve explanted from a patient during surgery for endocarditis showing clusters of cocci (*yellow*) clumped together and attached to the extracellular matrix covering the valve leaflet (magnification 5000×). Red blood cell showing in *red* color (Appendix E1).



**FIGURE 3.** A, Heatmap plots showing the difference in the expression of differentially abundant *Staphylococcus* genes between vegetation samples extracted from 3 patients with NVE and 3 patients with PVE during cardiac surgery. B, Difference in aureolysin (*aur*) expression in vegetation samples extracted from 3 patients with NVE and 3 patients with PVE during cardiac surgery.

bypass time (P < .0001), and more blood transfusion support (P < .0001) compared with surgery for NVE. Allograft is our preferred prosthesis for invasive PVE pathology to reconstruct the destroyed root and possibly resistance to reinfection, whereas focal invasion in NVE can be managed with a pericardial patch and aortic valve replacement. Patients with PVE required a longer length of stay in the intensive care unit (P = .034) and prolonged mechanical ventilation (P = .0008), but there was no difference in hospital death when compared with patients with NVE (P = .67). After multivariable adjustment of baseline variables, there was no difference in outcomes between the groups (Appendix E2, Tables E3 and E4).

# Transcriptomic Profiling of S. aureus in Cardiac Vegetations

We performed transcriptomic analyses of S. aureus isolated from cardiac valve vegetations harvested during surgery for left-sided endocarditis (a summary of the 6 patients' clinical data is presented in Table 1). We interrogated our data to compare the S. aureus transcriptional profile in native (n=3) versus prosthetic (n=3) valve vegetations: Prosthetic valve vegetation-colonizing bacteria demonstrated upregulation of genes responsible for biofilm formation (mnmA, secY), virulence factors (aur, pbpC), and stress response/metabolism (fbA, mnmA, fusA). Native valve vegetation-colonizing bacteria demonstrated upregulation of genes responsible for biofilm formation (dnaK,

agrA), virulence factors (clpB, spsA/SAOUHSC\_00902), cell division (ftsz), and stress response/metabolism (ahpC, pflD, thiW, pflB) (Figure 3, A, and Table E5).

# S. aureus Virulence Factor Aureolysin

Expression of *aur*, encoding for the metalloprotease aureolysin, was greater in prosthetic valve vegetation (3 patients) compared with native valve vegetation (3 patients) (P = .023) (Figure 3, B).


# Transcriptomic Profiling of S. aureus in Blood Cultures

We performed transcriptomic analyses of *S. aureus* isolated from blood cultures collected before surgery from the 6 subjects recruited in the study (3 patients with NVE and 3 patients with PVE). In NVE blood cultures, *S. aureus* upregulated genes responsible for biofilm formation (*dnak*, *ebpB*, *ebpA*), virulence factors (*fusA*, *clpB*), clumping (*clfB*), and stress response/metabolism (*cydB*, *raiA*). In PVE blood culture, *S. aureus* upregulated genes responsible for virulence factors and stress response (*aur*, *ahpC*) (Figure 4 and Table E6).

### **DISCUSSION**

# **Biofilm-Associated Endocarditis**

The initial event of IE pathogenesis is endothelial damage followed by aggregation of platelets and fibrin.<sup>2</sup> During periods of bacteremia, the site of thrombotic endocarditis



**FIGURE 4.** Heatmap plots showing the difference in the expression of differentially abundant *Staphylococcus* genes in blood culture samples collected from 3 patients with NVE and 3 patients with PVE before cardiac surgery.

becomes colonized by bacterial cells, which then grow as microcolonies clumping with platelets and fibrin meshwork and forming endocarditis vegetation (Figures 1 and 2). Currently, it is generally accepted that these microcolonies within the endocarditis vegetations grow as biofilm structures. This insight arose from multiple factors, such as the recognition of the role of biofilm in persistent infection, <sup>19</sup> a constellation of clinical observations that can be explained by a biofilm concept, <sup>3</sup> and growing evidence suggestive of biofilm involvement in IE, <sup>1</sup> including experimental work in animal models of IE or in vitro studies using clinical isolates from patients with endocarditis <sup>11,20,21</sup> and imaging studies. <sup>22,23</sup> Nevertheless, our study is the first to provide direct in vivo evidence by analyzing *S. aureus* transcriptome within cardiac vegetations.

# Understanding In Vivo Behavior of *S. aureus* in Infective Endocarditis

It is instrumental to study the expression of *S. aureus* virulence factors in patients because their expression patterns in animal models did not correspond to in vitro reports. <sup>24</sup> In addition, studying *S. aureus* colonizing cardiac vegetations provides a higher yield of clinically relevant

data without changes in gene expression that can be induced by growth culture conditions in blood cultures isolates or by systemic antibiotics that would have poor penetration into the vegetation biofilms. Transcriptomic analysis of S. aureus colonizing cardiac vegetation has shown antibiotic resistance genes such as pbpC (encoding a penicillinbinding protein) and fusA (conferring fusidic acid resistance) were upregulated in prosthetic valve vegetations compared with native valve vegetations. secY encodes for protein translocase subunit SecY, which is part of the general bacterial secretion system and impacts biofilm growth. fba encodes for fructose-bisphosphate aldolase, which supports bacterial metabolism during infection. Both secY and fba were upregulated in prosthetic valve vegetations. mnmA encodes for catalytic enzyme involved in protein synthesis and bacterial phenotypic traits including biofilm formation.<sup>25</sup>

agrA is a transcriptional activator of the agr quorum sensing system, the unique bacterial mechanisms for cell-to-cell communication that controls gene expression involved in population behaviors including biofilm formation and dispersion.<sup>26</sup> dnaK, which in involved in biofilm formation and adherence to eukaryotic cells, is a chaperone

TABLE 1. Clinical data of the specimens used for the transcriptomic analyses

| Subjects  | Preoperative antibiotics | Surgery   | Valve standard culture               | Valve universal bacterial PCR | Valve pathology   |
|---|--------------------------|---|--------------------------------------|-------------------------------|---|
| Case 1<br>Native left-sided<br>endocarditis     | Vancomycin               | Findings: vegetations and<br>perforation of aortic<br>valve leaflet<br>Procedure: AVR with<br>bioprosthesis   | Staphylococcus aureus                | S. aureus                     | Gram-positive cocci<br>clusters in fibrinous<br>vegetations         |
| Case 2<br>Native left-sided<br>endocarditis     | Vancomycin               | Findings: vegetation on<br>anterior mitral leaflet<br>Procedure: mitral valve<br>repair   | Mitral: Negative                     | Mitral: S. aureus             | N/A   |
| Case 3<br>Prosthetic left-sided<br>endocarditis | Vancomycin               | Findings: vegetation on<br>the mitral valve<br>prosthesis sewing cuff<br>Procedure: reoperation<br>mitral valve<br>replacement with<br>bioprosthesis            | Negative                             | S. aureus                     | Fibrinous vegetations,<br>clusters of bacterial<br>cocci            |
| Case 4<br>Prosthetic left-sided<br>endocarditis | Oxacillin                | Findings: vegetation on<br>the aortic valve<br>prosthesis, aortic root<br>abscess<br>Procedure: reoperation<br>aortic root replacement<br>with aortic allograft | S. aureus                            | S. aureus                     | Gram-positive cocci in clusters                                     |
| Case 5<br>Prosthetic left-sided<br>endocarditis | Oxacillin<br>Rifampin    | Findings: aortic root<br>abscess<br>Procedure: Reoperation<br>aortic root replacement<br>with aortic allograft  | Negative                             | S. aureus                     | Gram stain negative for micro-organisms                             |
| Case 6 Native left-sided endocarditis           | Vancomycin               | Findings: vegetations on<br>the mitral valve leaflets<br>Procedure: MVR with<br>bioprosthesis   | S. aureus Staphylococcus lugdunensis | S. lugdunensis                | Clusters of Gram-<br>positive cocci in the<br>fibrinous vegetations |

Universal Bacterial PCR, Bacterial DNA detected with 16s rRNA gene primer set; PCR, polymerase chain reaction; AVR, aortic valve replacement; N/A, not available; MVR, mitral valve replacement.

in the S. aureus heat shock system. In native valve vegetations, agrA and dnaK genes were upregulated, indicating biofilm formation in NVE, which is less widely accepted compared with biofilms in PVE. 11 Clp are ATPases involved in intracellular replication and stress response that contribute to pathogenicity of S. aureus colonizing native valve vegetations. <sup>27</sup> PflD and PflB are both part of pyruvate-formate-lyase, which is involved in fermentation and biofilm formation. Both were upregulated in native valve vegetations. The results of the transcriptomic analysis of the vegetation samples were supported by the transcriptomic analysis of the blood culture samples from the same 6 subjects, which showed upregulation of genes responsible for biofilm formation, and more important, upregulation of aur in PVE blood cultures. These findings suggest that S. aureus isolated from blood cultures was seeded from the valve vegetations.

# Aureolysin (aur)

The aur gene, which encodes for zinc metalloprotease aureolysin, was highly expressed in vegetations of PVE compared with NVE. Aureolysin is an important virulence factor responsible for evasion of host immune response, cleavage self-surface proteins (spread), and cleavage of host proteins (invasion). <sup>28,29</sup> Among all *S. aureus* proteases, aureolysin is the most effective virulence factors against complement cascade activation.<sup>30</sup> In addition to evasion of host immune response, aureolysin contributes to a phenomenon called "staphylocoagulation" via cleavage of prothrombin into thrombin, which enables S. aureus to be sealed within blood clots and escape phagocytosis.<sup>31</sup> In contrast, aureolysin activates urokinase and inactivates  $\alpha_2$ -antiplasmin and plasminogen activator inhibitor-1, which results in dissemination of bacterial cell and promotes pathogenic invasion of the host tissues.<sup>32</sup> Within

the context of IE, these properties contribute to S. aureus clumping within the vegetation meshwork, but more important they might be important factors in fragmentation of the vegetation that results in distal embolization phenomena. Additionally, aureolysin cleaves S. aureus surfaceassociated proteins that further promote the switch from adherent to mobile and invasive phenotype. 31,33 With these properties, aureolysin regulates the biofilm growth cycle through mediating both coagulation and dissemination while protecting against host immune defenses. Thus, aureolysin provides a crucial virulence factor for S. aureus pathogenicity and persistence. It also can explain the aggressive invasive pathology associated with PVE.<sup>5</sup> S. aureus uses proteolytic enzymes to degrade tissues to secure a nutrient source that can result in leaflet perforation or damage in NVE. In PVE, S. aureus proteolytic enzymes would degrade the tissues surrounding the prosthesis, which may result in abscess formation or valve dehiscence. This could provide an explanation for the difference in S. aureus virulence between NVE and PVE.

# **Clinical Implications**

The transcriptomic analysis supported by clinical pathology findings provides an invaluable in vivo demonstration of the tactics used by S. aureus to establish chronic infection and biofilm formation within cardiac vegetation in both NVE and PVE, and thus cannot be sterilized by antibiotics. Moreover, aureolysin production explains some of the associated phenomena of endocarditis, such as embolization and invasion. These findings should be taken into consideration when deciding on the timing for surgical intervention. Antibiotics can sterilize blood cultures, but not prosthetic valves colonized by S. aureus biofilm. Thus, delaying surgery for antibiotic response could result in progression of invasive pathology such as prosthesis dehiscence. The findings in this study suggest earlier intervention for PVE caused by S. aureus. Novel anti-biofilm therapeutics are under investigations that could be applied clinically in the future to control biofilm-associated infections. 11 Therapeutic targeting of S. aureus gene expression is an appealing approach to alter its virulence,<sup>34</sup> which highlights the importance of studying S. aureus transcriptome in IE.

In addition, the RNA-sequencing data of *S. aureus* virulence can set up the development of specific diagnostics to monitor the development of biofilm or invasive pathology (eg, aureolysin). In a novel study, Selan and colleagues<sup>35</sup> developed an enzyme-linked immunosorbent assay to detect antibodies against *S. aureus* biofilm antigens (slime polysaccharide antigens) in patients with surgical vascular graft infection. They have demonstrated elevated titers of immunoglobulin-M antibodies against *S. aureus* polysaccharide antigens in patients with ongoing infection as a sensitive and specific noninvasive diagnostic tool to detect *S. aureus* biofilm infection. Similar novel diagnostics can be

developed to detect development of biofilm in clinical IE or invasion based on further in vivo analysis of *S. aureus* virulence factors.

### Limitations

An important limitation to our study is the sample size. However, in this pilot study, we have demonstrated the feasibility of examining the in vivo gene expression of S. aureus in patients with IE using clinical samples, which are an invaluable resource to study molecular aspects of IE. Considering the small sample size and variability of gene expression among different samples, RNAsequencing data analysis was presented as abundance of gene expression in each group with percentage among the group samples. To avoid any bias of using one reference S. aureus genome of a specific taxa, RNA-sequencing analysis was performed using combined database of merged bacterial reference genomes. Gene expression in blood culture S. aureus isolates can be altered by culture methods (however, the same for NVE and PVE samples) and antibiotic therapy. The analysis of the Endocarditis Registry data is retrospective and limited by its observational nature, which is subject to investigator bias. Despite these limitations, this study provides the first in vivo analysis of S. aureus virulence within cardiac valve vegetations in patients with active IE. We examined S. aureus transcriptome as the most common organism causing IE with significant morbidity and mortality. 10 Other organisms that need to be studied are Streptococci and Enterococci, which together with S. aureus are responsible for 80% of IE.<sup>1</sup>

# **CONCLUSIONS**

Using a transcriptomics approach, we have demonstrated the feasibility to study in vivo virulence of S. aureus in clinical endocarditis. In this pilot study of 6 patients, S. aureus colonizing cardiac valve vegetations in both native and PVE expressed genes responsible for antibiotic resistance and biofilm formation. One critical virulence factor produced by S. aureus in IE, aureolysin, was highly expressed in PVE compared with NVE, which could explain the invasive pathology commonly associated with PVE. The results of the molecular analysis were complemented by clinical pathology data from a large surgical cohort of S. aureus endocarditis. The findings in this pilot study suggest a difference in S. aureus virulence between NVE and PVE, which could explain the difference in pathological features and outcomes. Better understanding of in vivo tactics used by S. aureus in IE can guide future studies dedicated to advance the current diagnostics and therapeutics to overcome this lethal disease.

# **Conflict of Interest Statement**

H.E. has a financial relationship with Edwards Lifesciences, Artivion, and LifeNet Health. All other authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

#### References

- Elgharably H, Hussain ST, Shrestha NK, Blackstone EH, Pettersson GB. Current hypotheses in cardiac surgery: biofilm in infective endocarditis. Semin Thorac Cardiovasc Surg. 2016;28(1):56-59. https://doi.org/10.1053/j.semtcvs.2015.12.005
- Cuervo G, Escrihuela-Vidal F, Gudiol C, Carratalà J. Current challenges in the management of infective endocarditis. Front Med. 2021;8:641243. https://doi. org/10.3389/fmed.2021.641243
- Elgharably H, Hussain ST, Shrestha NK, Pettersson GB. Biofilm in infective endocarditis and clinical implications. In: Shiffman M, Low M, eds. Biofilm, Pilonidal Cysts and Sinuses Recent Clinical Techniques, Results, and Research in Wounds. Springer; 2018:109-120.
- Hubers SA, DeSimone DC, Gersh BJ, Anavekar NS. Infective endocarditis: a contemporary review. *Mayo Clin Proc.* 2020;95(5):982-997. https://doi.org/10. 1016/j.mayocp.2019.12.008
- Pettersson GB, Hussain ST, Shrestha NK, et al. Infective endocarditis: an atlas of disease progression for describing, staging, coding, and understanding the pathology. *J Thorac Cardiovasc Surg*. 2014;147(4):1142-1149.e2. https://doi.org/ 10.1016/j.jtcvs.2013.11.031
- Hussain ST, Shrestha NK, Gordon SM, Houghtaling PL, Blackstone EH, Pettersson GB. Residual patient, anatomic, and surgical obstacles in treating active left-sided infective endocarditis. *J Thorac Cardiovasc Surg.* 2014; 148(3):981-988.e4. https://doi.org/10.1016/j.jtcvs.2014.06.019
- Witten JC, Tan CD, Rodriguez ER, et al. Invasive aortic valve endocarditis: clinical and tissue findings from a prospective investigation. *Ann Thorac Surg*. 2022; 113(2):535-543. https://doi.org/10.1016/j.athoracsur.2021.03.072
- Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. *Ann Thorac Surg.* 2012;93(2): 489-493. https://doi.org/10.1016/j.athoracsur.2011.10.063
- Weber C, Petrov G, Luehr M, et al. Surgical results for prosthetic versus native valve endocarditis: a multicenter analysis. *J Thorac Cardiovasc Surg.* 2021; 161(2):609-619.e10. https://doi.org/10.1016/j.jtcvs.2019.09.186
- Caceres Polo M, Thibault D, Jawitz OK, et al. Aortic prosthetic valve endocarditis: analysis of the Society of Thoracic Surgeons Database. *Ann Thorac Surg.* 2022;114(6):2140-2147. https://doi.org/10.1016/j.athoracsur.2021.10.

   045
- Lerche CJ, Schwartz F, Theut M, et al. Anti-biofilm approach in infective endocarditis exposes new treatment strategies for improved outcome. Front Cell Dev Biol. 2021;9:643335. https://doi.org/10.3389/fcell.2021.643335
- Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-638. https://doi.org/10.1086/313753
- Sangwan N, Zarraonaindia I, Hampton-Marcell JT, et al. Differential functional constraints cause strain-level endemism in polynucleobacter populations. mSystems. 2016;1(3):e00003-16. https://doi.org/10.1128/mSystems.00003-16
- Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. *Bioinformatics*. 2014;30(15):2114-2120. https://doi.org/10. 1093/bioinformatics/btu170
- Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014; 30(14):2068-2069. https://doi.org/10.1093/bioinformatics/btu153
- Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. https://doi.org/10.1093/bioinformatics/bts635

 Russel JT, Brejnrod AD, Bisgaard H, Sørensen SJ, Burmølle M. DAtest: a framework for choosing differential abundance or expression method. bioRxiv. 2018;241802. https://doi.org/10.1101/241802

- 18. Routledge R. Fisher's exact test. Encyclopedia of bostatistics. Wiley; 2005.
- Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318-1322.
- Di Domenico EG, Rimoldi SG, Cavallo I, et al. Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. BMC Microbiol. 2019;19(1):228. https://doi.org/10.1186/s12866-019-1596-2
- Azmi K, Qrei W, Abdeen Z. Screening of genes encoding adhesion factors and biofilm production in methicillin resistant strains of Staphylococcus aureus isolated from Palestinian patients. *BMC Genom.* 2019;20(1):578. https://doi.org/10. 1186/s12864-019-5929-1
- Bosio S, Leekha S, Gamb SI, Wright AJ, Terrell CL, Miller DV. Mycobacterium fortuitum prosthetic valve endocarditis: a case for the pathogenetic role of biofilms. *Cardiovasc Pathol*. 2012;21(4):361-364.
- Marrie TJ, Cooper JH, Costerton JW. Ultrastructure of cardiac bacterial vegetations on native valves with emphasis on alterations in bacterial morphology following antibiotic treatment. Can J Cardiol. 1987;3(6):275-280.
- Pragman AA, Schlievert PM. Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation. FEMS Immunol Med Microbiol. 2004;42(2):147-154. https://doi.org/10.1016/j.femsim.2004.05.005
- Benítez-Páez A, Belda-Ferre P, Simón-Soro A, Mira A. Microbiota diversity and gene expression dynamics in human oral biofilms. *BMC Genom.* 2014;15:311. https://doi.org/10.1186/1471-2164-15-311
- Yarwood JM, Schlievert PM. Quorum sensing in Staphylococcus infections. J Clin Invest. 2003;112(11):1620-1625. https://doi.org/10.1172/jci20442
- Frees D, Chastanet A, Qazi S, et al. Clp ATPases are required for stress tolerance, intracellular replication and biofilm formation in Staphylococcus aureus. Mol Microbiol. 2004;54(5):1445-1462. https://doi.org/10.1111/j.1365-2958.2004.04368.x
- Kolar SL, Ibarra JA, Rivera FE, et al. Extracellular proteases are key mediators of Staphylococcus aureus virulence via the global modulation of virulencedeterminant stability. *Microbiologyopen*. 2013;2(1):18-34. https://doi.org/10. 1002/mbo3.55
- Laarman AJ, Ruyken M, Malone CL, van Strijp JA, Horswill AR, Rooijakkers SH. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. *J Immunol*. 2011;186(11): 6445-6453. https://doi.org/10.4049/jimmunol.1002948
- Jusko M, Potempa J, Kantyka T, et al. Staphylococcal proteases aid in evasion of the human complement system. J Innate Immun. 2014;6(1):31-46. https://doi. org/10.1159/000351458
- Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem. 2002; 383(7-8):1075-1086. https://doi.org/10.1515/bc.2002.116
- Pietrocola G, Nobile G, Rindi S, Speziale P. Staphylococcus aureus manipulates innate immunity through own and host-expressed proteases. Front Cell Infect Microbiol. 2017;7:166. https://doi.org/10.3389/fcimb.2017.00166
- Potempa J, Shaw LN. Aureolysin. In: Rawlings ND, Salvesen G, eds. Handbook of Proteolytic Enzymes. Academic Press; 2013:563-569. Chapter 114.
- Arya R, Kim T, Youn JW, Bae T, Kim KK. Identification of an antivirulence agent targeting the master regulator of virulence genes in Staphylococcus aureus. Front Cell Infect Microbiol. 2023;13:1268044. https://doi.org/10.3389/fcimb.2023. 1268044
- Selan L, Passariello C, Rizzo L, et al. Diagnosis of vascular graft infections with antibodies against staphylococcal slime antigens. *Lancet*. 2002;359(9324): 2166-2168. https://doi.org/10.1016/s0140-6736(02)09086-4

**Key Words:** biofilm, infective endocarditis, invasion, *Staphylococcus*, virulence

### **APPENDIX E1**

# **Scanning Electron Microscope Imaging**

For scanning electron microscope imaging, an explanted valve prosthesis sample was obtained from an additional patient undergoing surgery for PVE. The explanted surgical sample was fixed in a 2.5% glutaraldehyde solution in 0.2 M phosphate buffer for 3 days. On the fourth day, samples were washed with 0.1 M phosphate buffer and dehydrated using graded concentrations of ethanol. Samples were washed with hexamethyldisilazane (Ted Pella Inc) and left to dry overnight. Before scanning, samples were mounted and coated with gold. A Helios NanoLab 650 system with a field-emission scanning electron microscope gun electro source and focused gallium-ion beam was used for imaging.

### **APPENDIX E2**

Although unadjusted duration of ICU stay is longer in PVE (median 141 hours) compared with NVE (median 97 hours), after multivariable regression analysis incorporating baseline differences, there is no difference between the groups (P=.22) (Table E5 shows parsimonious model after stepwise selection). Likewise, a multivariable logistic regression analysis for prolonged ventilation shows similar outcomes between the groups after adjusting for factors that are imbalanced at baseline (P=.20) (Table E6). No significant risk factors were found, but differences in the baseline characteristics were driving unadjusted results.

# **E-References**

- E1. Laarman AJ, Ruyken M, Malone CL, et al. Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion. *J Immu*nol. 2011;186(11):6445-6453. https://doi.org/10.4049/jimmunol.1002948
- E2. Kolar SL, Ibarra JA, Rivera FE, et al. Extracellular proteases are key mediators of Staphylococcus aureus virulence via the global modulation of virulencedeterminant stability. *Microbiologyopen*. 2013;2(1):18-34. https://doi.org/10. 1002/mbo3.55
- E3. Singh VK, Syring M, Singh A, Singhal K, Dalecki A, Johansson T. An insight into the significance of the DnaK heat shock system in Staphylococcus aureus. Int J Med Microbiol. 2012;302(6):242-252. https://doi.org/10.1016/j.ijmm.2012.05.001
- E4. Huang MB, Brena D, Wu JY, Shelton M, Bond VC. SMR peptide antagonizes Staphylococcus aureus biofilm formation. *Microbiol Spectr.* 2024; 12(2):e0258323. https://doi.org/10.1128/spectrum.02583-23
- E5. Usui M, Yoshii Y, Thiriet-Rupert S, Ghigo JM, Beloin C. Intermittent antibiotic treatment of bacterial biofilms favors the rapid evolution of resistance. *Commun Biol.* 2023;6(1):275. https://doi.org/10.1038/s42003-023-04601-y
- E6. Lama A, Pané-Farré J, Chon T, et al. Response of methicillin-resistant Staphy-lococcus aureus to amicoumacin A. PLoS One. 2012;7(3):e34037. https://doi.org/10.1371/journal.pone.0034037
- E7. Frees D, Chastanet A, Qazi S, et al. Clp ATPases are required for stress tolerance, intracellular replication and biofilm formation in Staphylococcus aureus. Mol Microbiol. 2004;54(5):1445-1462. https://doi.org/10.1111/j.1365-2958.2004.04368.x
- E8. Alam A, Bröms JE, Kumar R, Sjöstedt A. The role of ClpB in bacterial stress responses and virulence. Front Mol Biosci. 2021;8:668910. https://doi.org/10. 3389/fmolb.2021.668910
- E9. Kong C, Chee CF, Richter K, Thomas N, Abd Rahman N, Nathan S. Suppression of Staphylococcus aureus biofilm formation and virulence by a benzimidazole derivative, UM-C162. Sci Rep. 2018;8(1):2758. https://doi.org/10.1038/s41598-018-21141-2
- E10. Eswara PJ, Brzozowski RS, Viola MG, et al. An essential Staphylococcus aureus cell division protein directly regulates FtsZ dynamics. *Elife*. 2018; 7:e38856. https://doi.org/10.7554/eLife.38856

- E11. Zorrilla S, Monterroso B, Robles-Ramos M, Margolin W, Rivas G. FtsZ interactions and biomolecular condensates as potential targets for new antibiotics. Antibiotics (Basel). 2021;10(3):254. https://doi.org/10.3390/antibiotics10030254
- E12. Blättner S, Das S, Paprotka K, et al. Staphylococcus aureus exploits a non-ribosomal cyclic dipeptide to modulate survival within epithelial cells and phagocytes. *PLoS Pathog*. 2016;12(9):e1005857. https://doi.org/10.1371/journal.ppat.1005857
- E13. Benítez-Páez A, Belda-Ferre P, Simón-Soro A, Mira A. Microbiota diversity and gene expression dynamics in human oral biofilms. BMC Genom. 2014; 15:311. https://doi.org/10.1186/1471-2164-15-311
- E14. Schneewind O, Missiakas D. Sec-secretion and sortase-mediated anchoring of proteins in Gram-positive bacteria. *Biochim Biophys Acta*. 2014;1843(8): 1687-1697. https://doi.org/10.1016/j.bbamcr.2013.11.009
- E15. Rahman MA, Amirkhani A, Chowdhury D, et al. Proteome of Staphylococcus aureus biofilm changes significantly with aging. *Int J Mol Sci.* 2022;23(12): 6415. https://doi.org/10.3390/ijms23126415
- E16. Rajasree K, Fasim A, Gopal B. Conformational features of the Staphylococcus aureus AgrA-promoter interactions rationalize quorum-sensing triggered gene expression. *Biochem Biophys Rep.* 2016;6:124-134. https://doi.org/10.1016/j. bbrep.2016.03.012
- E17. Tan L, Li SR, Jiang B, Hu XM, Li S. Therapeutic targeting of the Staphylococcus aureus accessory gene regulator (agr) system. Front Microbiol. 2018; 9:55. https://doi.org/10.3389/fmicb.2018.00055
- E18. Peng Q, Tang X, Dong W, Sun N, Yuan W. A review of biofilm formation of Staphylococcus aureus and its regulation mechanism. *Antibiotics (Basel)*. 2022;12(1):12. https://doi.org/10.3390/antibiotics12010012
- E19. Bonar EA, Bukowski M, Hydzik M, et al. Joint genomic and proteomic analysis identifies meta-trait characteristics of virulent and non-virulent Staphylococcus aureus strains. Front Cell Infect Microbiol. 2018;8:313. https://doi.org/10.3389/ fcimb.2018.00313
- E20. Leibig M, Liebeke M, Mader D, Lalk M, Peschel A, Götz F. Pyruvate formate lyase acts as a formate supplier for metabolic processes during anaerobiosis in Staphylococcus aureus. J Bacteriol. 2011;193(4):952-962. https://doi.org/10. 1128/jb.01161-10
- E21. Capodagli GC, Lee SA, Boehm KJ, Brady KM, Pegan SD. Structural and functional characterization of methicillin-resistant Staphylococcus aureus's class IIb fructose 1,6-bisphosphate aldolase. *Biochemistry*. 2014;53(48):7604-7614. https://doi.org/10.1021/bi501141t
- E22. Tomlinson KL, Lung TWF, Dach F, et al. Staphylococcus aureus induces an itaconate-dominated immunometabolic response that drives biofilm formation. *Nat Commun.* 2021;12(1):1399. https://doi.org/10.1038/s41467-021-21718-y
- E23. Łeski TA, Tomasz A. Role of penicillin-binding protein 2 (PBP2) in the anti-biotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. *J Bacteriol*. 2005;187(5):1815-1824. https://doi.org/10.1128/jb.187.5.1815-1824.2005
- E24. Fishovitz J, Hermoso JA, Chang M, Mobashery S. Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. *IUBMB Life*. 2014;66(8): 572-577. https://doi.org/10.1002/iub.1289
- E25. Nasser A, Azimi T, Ostadmohammadi S, Ostadmohammadi S. A comprehensive review of bacterial osteomyelitis with emphasis on Staphylococcus aureus. *Microb Pathog*. 2020;148:104431. https://doi.org/10.1016/j.micpath.2020. 104431
- E26. Ch'ng JH, Muthu M, Chong KKL, et al. Heme cross-feeding can augment Staphylococcus aureus and Enterococcus faecalis dual species biofilms. *ISME J.* 2022;16(8):2015-2026. https://doi.org/10.1038/s41396-022-01248-1
- E27. Hammer ND, Reniere ML, Cassat JE, et al. Two heme-dependent terminal oxidases power Staphylococcus aureus organ-specific colonization of the vertebrate host. mBio. 2013;4(4):e00241-13. https://doi.org/10.1128/mBio.00241-13
- E28. Ní Eidhin D, Perkins S, Francois P, Vaudaux P, Höök M, Foster TJ. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. *Mol Microbiol*. 1998;30(2):245-257. https://doi.org/10.1046/j. 1365-2958 1998 01050 x
- E29. Basu A, Yap MN. Ribosome hibernation factor promotes Staphylococcal survival and differentially represses translation. *Nucleic Acids Res.* 2016;44(10): 4881-4893. https://doi.org/10.1093/nar/gkw180
- E30. Montealegre MC, La Rosa SL, Roh JH, Harvey BR, Murray BE. The Enterococcus faecalis EbpA pilus protein: attenuation of expression, biofilm formation, and adherence to fibrinogen start with the rare initiation codon ATT. mBio. 2015;6(3):e00467-15. https://doi.org/10.1128/mBio.00467-15

- E31. Cosgrove K, Coutts G, Jonsson IM, et al. Catalase (KatA) and alkyl hydroperoxide reductase (AhpC) have compensatory roles in peroxide stress resistance and are required for survival, persistence, and nasal colonization in Staphylococcus aureus. *J Bacteriol.* 2007;189(3):1025-1035. https://doi.org/10.1128/jb.01524-06
- E32. Hiltunen AK, Savijoki K, Nyman TA, et al. Structural and functional dynamics of Staphylococcus aureus biofilms and biofilm matrix proteins on different clinical materials. *Microorganisms*. 2019;7(12):584. https://doi.org/10.3390/mi croorganisms7120584

TABLE E1. Baseline characteristics of patients undergoing surgery for left-sided endocarditis caused by Staphylococcus aureus (n = 438)

|                                      | Native IE $(n = 260)$ |                      | Prosthetic IE $(n = 178)$ |                      |         |
|--------------------------------------|-----------------------|----------------------|---------------------------|----------------------|---------|
| Variable                             | n*                    | No. (%) or mean ± SD | n*                        | No. (%) or mean ± SD | P value |
| Demographics                         |                       |                      |                           |                      |         |
| Age (y)                              | 260                   | $52\pm15$            | 178                       | $56 \pm 14$          | .005    |
| Female                               | 260                   | 102 (39)             | 178                       | 51 (29)              | .02     |
| Body mass index (kg/m <sup>2</sup> ) | 260                   | $29 \pm 8.4$         | 177                       | $29 \pm 6.4$         | .41     |
| Race                                 | 254                   |                      | 170                       |                      | .53     |
| White                                |                       | 222 (87)             |                           | 152 (89)             |         |
| Black                                |                       | 24 (9.4)             |                           | 15 (8.8)             |         |
| Other                                |                       | 8 (3.1)              |                           | 3 (1.8)              |         |
| NYHA functional class                | 214                   |                      | 137                       |                      | .0003   |
| I                                    |                       | 69 (32)              |                           | 51 (37)              |         |
| II                                   |                       | 65 (30)              |                           | 41 (30)              |         |
| III                                  |                       | 36 (17)              |                           | 38 (28)              |         |
| IV                                   |                       | 44 (21)              |                           | 7 (5.1)              |         |
| Cardiac comorbidities                |                       |                      |                           |                      |         |
| Prior cardiac operations             | 260                   |                      | 178                       |                      | <.0001  |
| 0                                    |                       | 213 (82)             |                           | 0 (0)                |         |
| 1                                    |                       | 43 (17)              |                           | 120 (68)             |         |
| 2                                    |                       | 3 (1.2)              |                           | 43 (24)              |         |
| <u>≥</u> 3                           |                       | 1 (0.38)             |                           | 15 (8.4)             |         |
| Heart failure                        | 258                   | 127 (49)             | 178                       | 105 (59)             | .045    |
| Peripheral arterial disease          | 260                   | 46 (18)              | 178                       | 22 (12)              | .13     |
| Hypertension                         | 260                   | 171 (66)             | 178                       | 130 (73)             | .11     |
| LV ejection fraction (%)             | 256                   | $56 \pm 9.5$         | 172                       | $53 \pm 9.8$         | .0003   |
| Noncardiac comorbidities             |                       |                      |                           |                      |         |
| Preoperative creatinine†             | 260                   | 1.4 [0.8, 4.3]       | 178                       | 1.3 [0.9, 3.5]       | .66     |
| Preoperative BUN†                    | 260                   | 22 [12, 54]          | 178                       | 19 [12, 41]          | .008    |
| Preoperative bilirubin†              | 248                   | 0.5 [0.3, 1.1]       | 170                       | 0.7 [0.3, 1.5]       | .0008   |
| Preoperative hematocrit†             | 260                   | $29 \pm 4.5$         | 178                       | $30 \pm 4.7$         | .31     |
| History of smoking                   | 248                   | 143 (58)             | 173                       | 108 (62)             | .33     |
| Pharmacologically treated diabetes   | 257                   | 76 (30)              | 176                       | 42 (24)              | .16     |
| COPD                                 | 260                   | 44 (17)              | 178                       | 44 (25)              | .05     |
| Dialysis                             | 249                   | 60 (24)              | 169                       | 27 (16)              | .045    |
| Stroke                               | 259                   | 125 (48)             | 178                       | 86 (48)              | .99     |

IE, Infective endocarditis; NYHA, New York Heart Association; LV, left ventricle; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease. \*Patients with data available. †Median [15th, 85th] percentiles reported due to skewed distribution.

TABLE E2. Operative details and perioperative complications of patients who underwent surgery for left-sided endocarditis caused by  $Staphylococcus\ aureus\ (n=438)$ 

|  |     | Native IE $(n = 260)$ |     | Prosthetic IE (n = 178) |         |
|--|-----|-----------------------|-----|-------------------------|---------|
| Variable                               | n*  | No. (%) or mean ± SD  | n*  | No. (%) or mean ± SD    | P value |
| Valve involved                         | 260 |                       | 178 |                         | <.0001  |
| Aortic valve                           |     | 90 (35)               |     | 102 (57)                |         |
| Mitral valve                           |     | 135 (52)              |     | 34 (19)                 |         |
| Aortic and mitral valves               |     | 35 (13)               |     | 42 (24)                 |         |
| Pathological features                  |     |                       |     |                         |         |
| Invasive pathology                     | 260 | 104 (40)              | 178 | 135 (76)                | <.0001  |
| Vegetations                            | 260 | 242 (93)              | 178 | 143 (80)                | <.0001  |
| Cavity formation                       | 260 | 27 (10)               | 178 | 79 (44)                 | <.0001  |
| Surgery                                |     |                       |     |                         |         |
| AVR with allograft                     | 137 | 51 (37)               | 149 | 121 (81)                | <.0001  |
| AVR with mechanical valve              | 137 | 4 (2.9)               | 149 | 3 (2.0)                 | .56     |
| AVR with bioprosthetic valve           | 137 | 72 (53)               | 149 | 24 (16)                 | <.0001  |
| Cardiopulmonary bypass (min)           | 259 | $133 \pm 62.8$        | 178 | $202 \pm 75.3$          | <.0001  |
| Perioperative transfusion (RBC units)† | 260 | 4 [1, 12]             | 178 | 7 [3, 18]               | <.0001  |
| Outcomes                               |     |                       |     |                         |         |
| ICU length of stay (h)†                | 260 | 97 [30, 406]          | 177 | 141 [45, 546]           | .034    |
| Prolonged ventilation >24 h            | 258 | 100 (39)              | 176 | 97 (55)                 | .0008   |
| Renal dysfunction requiring dialysis   | 189 | 17 (9)                | 142 | 17 (12)                 | .38     |
| Septicemia                             | 260 | 25 (10)               | 178 | 17 (10)                 | >.9     |
| Stroke                                 | 260 | 17 (7)                | 178 | 9 (5)                   | .52     |
| Hospital death                         | 260 | 19 (7)                | 178 | 15 (8)                  | .67     |

IE, Infective endocarditis; AVR, aortic valve replacement; RBC, red blood cell; ICU, intensive care unit. \*Patients with data available. †Median [15th, 85th] percentiles.

TABLE E3. Linear regression model for risk factors of intensive care unit stay

|                                 | Parameter |         |         |
|---------------------------------|-----------|---------|---------|
| Factor                          | estimate  | SE      | P value |
| PVE (vs NVE)                    | -0.24336  | 0.19832 | .22     |
| Patient age at date of surgery  | 0.01401   | 0.00453 | .002    |
| Total No. of cardiac operations | 0.21660   | 0.11512 | .06     |
| Intercept*                      | 3.70160   | 0.28896 | <.0001  |

PVE, Prosthetic valve endocarditis; NVE, native valve endocarditis. \*Outcome modeled as log(ICU stay) in hours.

TABLE E4. Logistic regression model for risk of prolonged ventilation

| Factor                           | Parameter estimate | SE      | Wald chi-square | P value |
|----------------------------------|--------------------|---------|-----------------|---------|
| PVE (vs NVE)                     | 0.3727             | 0.2895  | 1.65            | .20     |
| Patient's age at date of surgery | 0.0129             | 0.00661 | 3.79            | .05     |
| Total No. of cardiac operations  | 0.1815             | 0.1661  | 1.19            | .27     |
| Intercept                        | -1.3542            | 0.4257  | 10.12           | .0015   |

C-statistic = 0.61. PVE, Prosthetic valve endocarditis; NVE, native valve endocarditis.

TABLE E5. List of the top differentially expressed  $Staphylococcus \ aureus$  genes in native (n=3) and prosthetic (n=3) valve vegetations, and related biological functions

| Gene name | Gene function/protein              | Biological function  | References |
|-----------|------------------------------------|--|------------|
| aur       | Zinc metalloproteinase aureolysin  | Evasion of host immune response, cleavage self-surface proteins (spread), cleavage of host proteins (invasion) | E1,E2      |
| dnaK      | Molecular chaperone DnaK           | Stress response (heat shock protein), biofilm formation  | E3,E4      |
| fusA      | Elongation factor G'               | Protein synthesis, antibiotic resistance, biofilm survival   | E5,E6      |
| clpB      | Chaperone protein ClpB             | Stress response, intracellular multiplication, regulation of virulence factors expression                      | E7-E9      |
| ftsZ      | Cell division protein FtsZ         | Bacterial cell division, persisters growth   | E10,E11    |
| spsA      | Signal peptidase I (SAOUHSC_00902) | Contribute to phagosomal escape, intracellular survival  | E12        |
| mnmA      | tRNA-specific 2-thiouridylase MnmA | Protein synthesis, bacterial phenotypic traits including biofilm formation                                     | E13        |
| secY      | Protein translocase subunit SecY   | Quorum sensing, bacterial secretion systems, and protein export  | E14,E15    |
| agrA      | Accessory gene regulator protein A | Quorum sensing, biofilm formation  | E16-E18    |
| pflD      | Formate C-acetyltransferase        | Metabolism   | E19        |
| pflB      | Formate acetyltransferase          | Metabolism, biofilm tolerance to anaerobic conditions  | E20        |
| fbA       | Fructose-bisphosphate aldolase     | Metabolism during infection  | E21,E22    |
| pbpC      | Penicillin-binding protein 2       | Cell wall biosynthesis and resistance to antimicrobial   | E23,E24    |

TABLE E6. List of the top differentially expressed Staphylococcus aureus genes in blood cultures from patients with native (n=3) and prosthetic (n=3) valve endocarditis, and related biological functions

| Gene name | Gene function/protein   | Biological function  | References |
|-----------|---|--|------------|
| dnak      | Molecular chaperone DnaK  | Stress response (heat shock protein), biofilm formation  | E3,E4      |
| ebpB      | Endocarditis and biofilm-associated pilus minor subunit EbpB    | Pilus biogenesis, biofilm formation  | E25        |
| cydB      | Cytochrome d ubiquinol oxidase, subunit II                      | Aerobic respiration, virulence factor for colonization, augmentation of multi-species biofilm                  | E26,E27    |
| clfB      | Clumping factor B   | Attachment to human fibrinogen, promote bacterial clumping   | E28        |
| raiA      | Ribosome hibernation promotion factor                           | Promote survival, recalcitrance, and infection relapse   | E29        |
| clpB      | Chaperone protein ClpB  | Stress response, intracellular multiplication, regulation of virulence factors expression                      | E7-E9      |
| ebpA      | Endocarditis and biofilm-associated pilus tip protein subunit A | Pilus biogenesis, biofilm formation  | E30        |
| fusA      | Elongation factor G'  | Protein synthesis, antibiotic resistance, biofilm survival   | E5,E6      |
| aur       | Zinc metalloproteinase aureolysin                               | Evasion of host immune response, cleavage self-surface proteins (spread), cleavage of host proteins (invasion) | E1,E2      |
| ahpC      | Alkyl hydroperoxide reductase C                                 | Oxidative stress response, biofilm virulence   | E31,E32    |